Spero Therapeutics (Nasdaq: SPRO) announced that its Board Compensation Committee approved an inducement equity grant under the 2019 Inducement Equity Incentive Plan to a new employee. Effective August 3, 2026, the grant consists of 324,622 stock options and 162,311 restricted stock units (RSUs), made in accordance with Nasdaq Listing Rule 5635(c)(4), which permits equity awards as a material inducement to employment for individuals not previously employed by the company.
The stock options vest 25% on August 3, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued employment. The RSUs vest in four equal annual installments beginning August 3, 2027, also contingent on continued employment. Both the options and RSUs are governed by the terms of the 2019 Inducement Plan and the related award agreements.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
-22.02% was SPRO's recorded 24-hour reaction to a financing announcement, while other recent company...
Analysis
-22.02% was SPRO's recorded 24-hour reaction to a financing announcement, while other recent company announcements also had negative reactions. The current employee grant is best viewed alongside that history; low short positioning was separate risk context.
"162,311 restricted stock unit awards (RSUs) to a new employee"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
nasdaq listing rule 5635(c)(4)regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that on July 22, 2026, the Compensation Committee of Spero’s Board of Directors approved a grant, to be made on August 3rd, of an aggregate of 324,622 stock options and 162,311 restricted stock unit awards (RSUs) to a new employee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended (2019 Inducement Plan). The stock options and RSUs are being granted as an inducement material to Spero’s new employee in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Spero (or following a bona fide period of non-employment), as a material inducement for such individuals entering into employment with Spero, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
The shares underlying the option vest as to 25% on August 3, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the employee’s continued employment with Spero through the applicable vesting dates.The RSUs will vest in four equal annual installments beginning on August 3, 2027, subject to the employees‘ continued employment with Spero through the applicable vesting dates. The stock options and the RSUs are subject to the terms and conditions of the 2019 Inducement Plan and the stock option and the RSU agreement covering the grant.
About Spero Therapeutics Spero Therapeutics is a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for patients with serious immune-mediated diseases. The company’s lead program, SP001, is a third-generation, Fc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related disease, with potential for development in additional immunological & inflammatory diseases. For more information, visit www.sperotx.com
What equity awards did Spero Therapeutics (SPRO) grant under Nasdaq Listing Rule 5635(c)(4) on August 3, 2026?
Spero Therapeutics granted 324,622 stock options and 162,311 RSUs to a new employee. According to Spero Therapeutics, these awards were issued under its 2019 Inducement Equity Incentive Plan as a material inducement to employment consistent with Nasdaq Listing Rule 5635(c)(4).
How do the Spero Therapeutics (SPRO) inducement stock options granted in July 2026 vest?
The inducement stock options vest 25% on August 3, 2027, with the remaining 75% vesting in 36 equal monthly installments. According to Spero Therapeutics, vesting is contingent on the employee’s continued employment through each applicable vesting date under the 2019 Inducement Plan.
What is the vesting schedule for the RSUs in Spero Therapeutics’ August 2026 inducement grant (SPRO)?
The RSUs vest in four equal annual installments starting August 3, 2027. According to Spero Therapeutics, each installment is subject to the employee’s continued employment through the applicable vesting date and is governed by the 2019 Inducement Equity Incentive Plan and award agreement.
Why did Spero Therapeutics use the 2019 Inducement Equity Incentive Plan for this SPRO grant?
Spero Therapeutics used the 2019 Inducement Plan to grant equity awards as a material inducement to a new hire. According to Spero Therapeutics, the plan is used exclusively for individuals not previously employed by the company, in line with Nasdaq Listing Rule 5635(c)(4).
Does the Spero Therapeutics (SPRO) August 2026 inducement grant require continued employment for vesting?
Yes, both the stock options and RSUs require continued employment for vesting. According to Spero Therapeutics, option vesting and RSU vesting occur only if the employee remains employed through the specified vesting dates set out in the plan and agreements.
Who approved the July 22, 2026 inducement equity grant at Spero Therapeutics (SPRO)?
The Compensation Committee of Spero Therapeutics’ Board of Directors approved the inducement grant on July 22, 2026. According to Spero Therapeutics, the grant was then made effective August 3, 2026 under the company’s 2019 Inducement Equity Incentive Plan.
